Blog

Anveshan is a Gurugram-based D2C food brand that sells minimally processed staples such as A2 bilona ghee, cold-pressed oils, raw honey, atta, and other traditional pantry products. This Anveshan funding round matters because everyday food is still a trust problem. Buyers want cleaner labels and better sourcing, but most staples are sold through opaque supply chains. The company has now raised ₹150 crore in a Series B. Vertex Ventures Southeast Asia & India led the round, with IFC, Swiggy cofounder Sriharsha Majety, and existing backers Wipro Consumer Care Ventures, Titan Capital Winners Fund, Force Ventures, Aman Gupta, and Sameer Mehta also joining. Founded in 2020 by Kuldeep Parewa, Akhil Kansal, and Aayushi Khandelwal, Anveshan is already running at ₹280-300 crore in annual revenue and wants to push that to ₹1,000 crore within 24-30 months.

What is Anveshan and how does it work?

Anveshan isn’t trying to invent a new food category. It’s taking old Indian staples and rebuilding the supply chain around them. The company sources from farmers and rural producers. It processes products closer to origin through distributed micro-units. It tests batches before sale, then pushes them through its own website, ecommerce marketplaces, and quick commerce apps. That matters because the brand is selling trust as much as ghee or oil.

The product mechanics are unusually specific for a consumer brand. Its oils are cold-pressed below 40°C, which is meant to preserve more of the original nutritional profile. Its ghee is made with the bilona method over roughly 30 hours in small batches, rather than using high-speed industrial shortcuts. That’s a slower, more expensive way to build a food business. But it gives Anveshan a clean angle that generic pantry brands struggle to fake.

Quality control is another part of the pitch. Every batch goes through 17+ checks, including tests tied to A2 protein, solids-not-fat levels, antioxidant content, heavy metals, and pesticide contamination. The company has also been talking about end-to-end traceability for years, and even its earlier funding was used in part to improve supply chain and traceability systems. Put simply, it’s trying to turn a category built on faith into one built on verification.

For customers, the experience is straightforward. Instead of buying loose or lightly labeled staples and hoping they’re pure, shoppers get a branded product marketed around source transparency, traditional processing, and lab-backed checks. That mix has worked across digital channels. Anveshan already gets about 30% of sales from its own site, another 30% from ecommerce, and 30-40% from quick commerce.

How did Anveshan start and who are the founders?

The founding story

Anveshan was started in 2020 by Kuldeep Parewa, Akhil Kansal, and Aayushi Khandelwal, all IIT Guwahati alumni. The original thesis was direct: Indian households were paying up for “healthy” food, but they still had weak visibility into sourcing, processing, and product integrity. So the founders built a brand around minimally processed staples and a farm-linked manufacturing model instead of chasing the usual snack-brand playbook.

That’s also why the company’s product mix looks the way it does. It began with trust-heavy categories like ghee, oils, and honey—products where consumers worry about adulteration and quality, and where traditional methods still carry real weight in buying decisions. Now it’s widening into atta and other nutrition-led staples without moving too far from that original promise.

Why the founders had a believable angle

The team had stronger market fit than “IIT grads start food brand” might suggest at first glance. Aayushi Khandelwal came from Goldman Sachs before cofounding Anveshan, while Kuldeep Parewa’s public profile points to a product and technology background alongside entrepreneurship. Akhil Kansal has been the most vocal founder on sustainable supply chains, customer feedback, and disciplined D2C execution. It’s not a classic FMCG pedigree. But it is a useful mix for building a digitally native pantry brand that depends on operations, storytelling, and unit economics all at once.

Traction before the new money

The numbers are moving fast. For the year ended March 2025, Anveshan’s operating revenue rose 64.6% to ₹77.08 crore from ₹46.84 crore in FY24, while losses widened to ₹11.88 crore from ₹5.74 crore. That widening loss line isn’t unusual for a brand still investing in manufacturing, distribution, and category expansion. But scale alone won’t settle the debate around efficiency.

Still, the top-line momentum is real. The company is currently operating at a ₹280-300 crore annual revenue run rate and is aiming for ₹1,000 crore in revenue within the next 24-30 months. ET also reported that Anveshan is expected to close FY26 at ₹200-220 crore in revenue, and that roughly 50-55% of its business now comes from tier 2 and tier 3 cities. That’s a useful signal. This isn’t just an urban premium-food brand anymore.

The footprint is no longer tiny either. Anveshan has 16 manufacturing plants across 9 states, and its broader model has supported 7,000+ farmers through fairer sourcing and village-linked micro-processing. That’s a hard setup to replicate quickly if demand keeps growing.

Fundraising details

The new ₹150 crore round is a Series B. Vertex Ventures Southeast Asia & India led it. IFC joined in, along with Sriharsha Majety and existing investors Wipro Consumer Care Ventures, Titan Capital Winners Fund, Force Ventures, Aman Gupta, and Sameer Mehta. Entrackr had reported the development earlier and estimated the valuation at more than $90 million.

This isn’t Anveshan’s first meaningful institutional backing. It raised ₹3.67 crore in seed funding in 2021 from DSG Consumer Partners, Titan Capital, and others. Then in April 2025 it raised ₹48 crore in a Series A led by Wipro Consumer Care Ventures, with existing investors returning. The new capital is meant for manufacturing and product development. It will also go toward offline expansion, digital growth, sourcing infrastructure, procurement systems, quality assurance, testing, and deeper partnerships with micro entrepreneurs and traditional producers.

Where it sits against rivals

Anveshan isn’t alone in this category. ET has placed it against names like Two Brothers Organic Farms, Tata Sampann, and Organic Mandya. And that feels about right. The competition isn’t just startup-to-startup either. It includes legacy FMCG pantry brands, local unbranded staples, and premium subscription-first players such as Country Delight that also sell “better” everyday food.

Its real differentiator is the messy middle between farm sourcing and branded trust. Not the lowest price. Not the widest assortment. It’s betting on controlled processing, testing, and a distributed rural production network. Investors are backing the idea that in staples, credibility can become a moat if the supply chain is hard to copy.

Why is Anveshan funding attracting investors now?

Because this round is about infrastructure, not just marketing.

A lot of consumer startups raise money to buy growth through ads and discounting. Anveshan plans to use the capital to strengthen manufacturing, sourcing, procurement, testing, and offline distribution. That suggests the company wants tighter control over product integrity as it scales. That’s exactly where clean-label brands usually stumble. If you promise purity and then lose grip on the back end, the brand breaks fast.

There’s also a channel shift here. Anveshan already has a meaningful quick-commerce mix, but it now wants to grow offline harder while keeping its owned digital business strong. That’s a smart move. Clean-label pantry products often begin online, where storytelling is easier, but real scale in India still comes when customers can find the brand across more routine shopping touchpoints.

How big is the market behind Anveshan funding?

The market tailwind is obvious. IMARC pegs India’s organic food market at $1.92 billion in 2024 and projects it to reach about $10.81 billion by 2033, which implies a 20.13% CAGR. That’s not a niche curve anymore. It shows consumers are steadily moving toward foods that feel safer, cleaner, and more transparent.

The broader packaged-food shift may be even more relevant than the organic number. Redseer says India’s packaged food and beverages market is already worth more than $100 billion. It also found that 2 out of 3 millennials are willing to pay about a 15% premium for cleaner ready-to-cook and ready-to-eat products, while 8 out of 10 mothers in Bharat have reduced refined oil use in favor of options like mustard oil, groundnut oil, and desi ghee. That’s almost a perfect demand signal for a brand built around pantry staples and processing claims.

What should you watch after Anveshan funding?

The headline is ₹150 crore. The real test is whether Anveshan can turn clean-label trust into a much larger, still-disciplined food business.

It has momentum, decent category timing, and investors who think staples can still be rebuilt from the supply side out. But the next stretch won’t be about storytelling alone. Watch manufacturing expansion, offline execution, and whether Anveshan funding helps the company grow without letting losses outrun the brand’s credibility.

Read how Groq is seeking up to $650M to expand its AI inference cloud business built on custom LPU chips designed for fast, low-cost AI responses at scale.

FAQ

– What is the latest Anveshan funding round?  

 Anveshan has raised ₹150 crore in a Series B round announced on June 1, 2026. Vertex Ventures Southeast Asia & India led the round, and IFC, Sriharsha Majety, Wipro Consumer Care Ventures, Titan Capital Winners Fund, Force Ventures, Aman Gupta, and Sameer Mehta also participated.

– How does Anveshan make its products?  

 Anveshan uses traditional and low-intervention processing methods for core categories. Its oils are cold-pressed below 40°C, its bilona ghee takes roughly 30 hours to produce in small batches, and each batch goes through more than 17 quality checks before sale.

– Who founded Anveshan?  

 Anveshan was founded in 2020 by Kuldeep Parewa, Akhil Kansal, and Aayushi Khandelwal, who are all IIT Guwahati alumni. Khandelwal previously worked at Goldman Sachs, which gives the founding team a mix of consumer insight, operations thinking, and finance discipline.

– Is Anveshan a D2C brand or an FMCG company?  

 It’s best understood as a D2C-first clean-label food brand that’s expanding into a broader FMCG-style footprint. The company already sells through its own website, ecommerce, and quick-commerce channels, and this new round is meant in part to accelerate offline distribution as well.

Groq runs AI models on its own LPU chips. It provides fast inference services to developers and enterprises.

Groq is seeking up to $650 million from existing investors. The company is focusing more on its AI inference cloud business. It believes AI profits will come from serving fast, low-cost responses at scale.

Groq was founded in 2016 by Jonathan Ross, who helped launch Google’s original TPU project, and Douglas Wightman, a former Google X engineer and Groq’s first CEO.

That founding pedigree matters. So does timing.

What is Groq’s AI inference cloud and how does it work?

At the product level, Groq sells access to GroqCloud, a hosted inference platform powered by its in-house Language Processing Unit, or LPU. Developers don’t have to learn a weird new stack to use it. Groq’s API is designed to be largely OpenAI-compatible, so a team can point an existing app at Groq’s base URL and choose a supported model. Then it can send a chat or responses request and start getting outputs back with very little integration work.

That’s the basic flow. But the product is broader than plain text generation. Groq’s docs now group the platform around text generation and speech-to-text. It also includes text-to-speech, OCR and image recognition, reasoning, content moderation, structured outputs, and prompt caching. It’s trying to look less like a single-purpose speed demo and more like a usable production layer for AI apps.

The newer Compound system pushes that a step further. Groq offers `groq/compound` and a lighter `groq/compound-mini`, which can automatically call built-in tools like web search and website visiting. It also supports code execution, browser automation, and Wolfram Alpha. In plain English, that means developers can offload some of the agent plumbing to Groq’s platform instead of wiring every tool call themselves.

Groq’s hardware story still matters here. Its LPU architecture was built from the ground up for inference, with deterministic compute and networking. It also uses on-chip memory and a generic compiler that avoids the model-specific kernel work GPUs often need. That doesn’t guarantee commercial success. But it explains the pitch: less infrastructure mess, less latency variability, and faster time to a working app.

Who founded Groq and why did they build it?

Founding story

Groq started in Mountain View in 2016 with a very specific thesis: inference would become its own massive computing category, and standard GPU architecture wouldn’t always be the right answer for it. Ross and Wightman came out of Google’s hardware and moonshot culture, so this wasn’t a random startup idea cooked up after ChatGPT. It was an early bet that AI serving would eventually deserve dedicated silicon and dedicated systems.

Why the founders had market fit

Ross was the obvious technical anchor. Before Groq, he began what became Google’s TPU effort as a side project, designed core elements of the original chip, and later joined Google X’s Rapid Eval Team. He also studied mathematics and computer science at NYU’s Courant Institute. That mix — deep chip design, systems thinking, and some genuine first-principles obsession — is exactly the kind of background investors want when the product is custom AI hardware plus cloud software.

Wightman brought different credibility. He was a former Google X engineer and an early operating leader inside Groq, serving as the company’s first CEO. There isn’t much public detail on prior company-building wins beyond that. The stronger disclosed signal is the founders’ domain expertise in advanced computing and experimental systems.

Traction, fundraising history, and competition

Groq’s business model has already changed once. By August 2024, Ross said the company had decided to focus mostly on selling cloud access to developers rather than trying to push hardware directly into customer hands, and he said the cloud service had grown to 350,000 developers. By September 2025, Groq said it powered more than 2 million developers and Fortune 500 companies, with data center operations across North America, Europe, and the Middle East.

The capital followed that shift. Groq raised $640 million in a Series D led by BlackRock funds in August 2024 at a $2.8 billion valuation. Then it announced another $750 million in September 2025 at a $6.9 billion post-money valuation led by Disruptive, with BlackRock, Neuberger Berman, DTCP, Samsung, Cisco, D1, Altimeter, 1789 Capital, and Infinitum among the backers. That’s a lot of money. Groq still had to prove it could turn technical speed into durable cloud revenue.

Competition is brutal. Cerebras is building a dedicated inference cloud and said in March 2025 that it was launching 6 new inference datacenters as part of a 20x capacity expansion plan. Together AI raised a $305 million Series B in February 2025 and sells both serverless and dedicated inference on a GPU-heavy cloud. SambaNova has been pitching turnkey inference products for data centers that it says can be deployed in 90 days. Then there are the giant incumbents — AWS, Microsoft Azure, Google Cloud — plus specialized AI clouds like CoreWeave.

What’s different about Groq is this: unlike GPU neoclouds that rent or resell Nvidia-heavy infrastructure, Groq’s claim is that it controls the stack from silicon to serving layer. Investors aren’t just backing another AI hosting provider. They’re backing the idea that purpose-built inference hardware can produce a real speed-and-cost edge in production.

What does the new Groq funding round include?

The latest plan is a new raise of up to $650 million from existing investors. The money is meant to support Groq’s next chapter as an inference neocloud — basically a slimmer company focused on hosting inference-hungry applications for developers and enterprises, rather than trying to be a broad standalone chip company again.

That push comes after Groq’s December 2025 deal with Nvidia, which was structured as a non-exclusive licensing agreement rather than a full acquisition. The reported value was around $20 billion, some top Groq leaders went to Nvidia, and Groq shareholders received payouts even though no equity changed hands. Weird deal. Very lucrative one.

Groq’s current direction is being steered by interim CEO Adam Winter and interim CFO Matt Eng. The round also looks unusually de-risked for a private financing: Disruptive and Infinitium have agreed to backstop it if other existing investors don’t take their pro-rata allocations. That’s not a small detail. It means Groq isn’t just testing investor appetite — it’s lining up insurance behind the plan.

Why are investors backing this AI inference cloud bet now?

Part of the answer is that Groq had already been moving this way before the Nvidia transaction. The 2024 shift toward cloud usage, followed by the 2025 claim of more than 2 million developers on the platform, gave investors a live business to underwrite instead of a pure hardware moonshot. That makes this round feel more like scaling capital than rescue capital.

There’s also a cleaner post-Nvidia story here. Groq has already monetized part of its hardware value through the licensing agreement, paid investors, and stayed alive as an independent company. So this raise is effectively a bet on “Groq 2.0” — the version that keeps the inference platform, keeps the chip advantage, and tries to build a more recurring cloud business around them.

But the risk didn’t disappear. A company that loses senior leadership in a giant licensing deal still has to prove it can execute. Groq now has to show that speed benchmarks, clever architecture, and a familiar developer API can translate into sustained enterprise demand in a market full of better-capitalized rivals.

How big is the AI inference cloud market?

The macro case is pretty straightforward. McKinsey projects AI inference demand in data centers will jump from 20.9 GW in 2025 to 93.3 GW in 2030, a 35% CAGR, and says inference will overtake non-AI workloads by 2029. By 2030, it expects inference to represent more than 40% of total data center demand.

That matters because inference has different economics than training. It favors low latency and metro and near-metro deployment. It also rewards network efficiency and hardware that can keep serving requests all day without burning ridiculous amounts of power. Workload-specific accelerators and tighter software-hardware integration start looking a lot more attractive in that kind of market. That’s the opening Groq has been chasing since 2016.

Groq’s inference cloud story is a lot sharper now than it was a year ago. After the Nvidia deal, the company no longer has the luxury of being vague about its future — it has to prove that the remaining business can scale as a real cloud platform, not just as an impressive chip demo. The next 12 months will show whether that means capacity growth, enterprise adoption, and sticky usage instead of another flashy funding headline.

Read how H1 raised a $40M round led by CVS Health Ventures to help pharma companies, hospitals, and health plans turn fragmented physician and provider data into actionable healthcare intelligence.

FAQ

– What is Groq raising right now?  

 Groq is seeking up to $650 million in new financing from existing investors. The round follows the company’s December 2025 Nvidia licensing deal, and Disruptive plus Infinitium have agreed to backstop any unsold portion if other shareholders don’t take their pro-rata stakes.

– How does Groq’s AI inference cloud work?  

 Groq runs AI models through GroqCloud, a hosted service built on its own LPU chips, and exposes that capacity through an API that is largely compatible with OpenAI-style integrations. Customers can use it for text generation and other workloads like speech, OCR, and tool-using agent flows without rebuilding their entire application stack.

– Who founded Groq?  

 Groq was founded in 2016 by Jonathan Ross and Douglas Wightman. Ross is best known for helping start Google’s TPU effort before moving through Google X, while Wightman came from Google X and served as Groq’s first CEO.

– Why is Groq part of the AI inference cloud market instead of just the AI chip market?  

 Because Groq has been moving toward selling cloud access, not only silicon, for a while now. The company said in 2024 that it was emphasizing cloud services for developers, and the current financing push shows that management and investors think recurring inference demand — not just one-off chip sales — is where the business can grow next.

The H1 healthcare data platform sells physician and provider intelligence to pharma companies, hospital systems, health plans, and digital health firms. H1 has now raised a new $40 million round led by CVS Health Ventures at a moment when older SaaS startups are getting ignored and AI-native companies are soaking up most of the hype. The pitch is simple: fragmented doctor data still creates expensive mistakes, and that problem hasn’t gone away just because generative AI showed up. Founded in New York in 2017 by Ariel Katz and Ian Sax, H1 is trying to prove that a real data moat still matters.

What does the H1 healthcare data platform do?

The H1 healthcare data platform is basically a giant operating layer for figuring out which doctors matter for a given healthcare decision. A customer starts with a question — which physicians lead research in a disease area, which trial sites have the right investigators, which doctors prescribe a therapy, or which providers are actually in-network. H1 pulls together fragmented healthcare professional, clinical, scientific, and provider data. Then it turns that into searchable profiles and workflow-specific recommendations.

That data is packaged into product lines instead of one generic dashboard. H1 for Medical helps medical affairs teams find and engage key opinion leaders. H1 for Clinical is built around site selection and principal investigator discovery. It also covers participant recruitment and more representative trials. H1 for Commercial is aimed at helping life sciences teams launch therapies and improve patient access. After the Ribbon deal, H1 also added H1 for Health Plans & Digital Health, pushing deeper into accurate provider data for insurers and care-navigation companies.

That’s the part Katz is leaning on in the AI debate. A workflow layer can get copied fast. A global, constantly refreshed doctor and provider knowledge base is harder to fake. H1 frames the product around operational questions customers ask every day — who should run a trial, who is emerging in a specialty, which hospital has prior trial activity, and whether a provider directory is actually accurate.

Before tools like this, a lot of that work lived in spreadsheets, vendor files, rep notes, public registries, and manual phone verification. On the payer side, H1 now talks openly about directory management and rosters. Credentialing, network management, and provider data management are core workflows too. That’s not glamorous software. But it’s the kind of operational plumbing big healthcare organizations spend years trying to clean up.

Who founded H1 and why did it start?

H1’s founding story

H1 was started in 2017 by Ariel Katz and Ian Sax. The company’s core idea was that healthcare runs on relationships and expertise, yet the information needed to find the right doctor was scattered, stale, and oddly manual. H1 built around that gap from day 1 — not as a generic CRM layer, but as a data company built to connect life sciences teams, providers, payers, and patients with the right healthcare professional faster.

Why Ariel Katz looked credible from the start

Katz wasn’t a first-time founder learning how to sell software on the fly. Before H1, he started ResearchConnection while still in college, and that company expanded to more than 40 universities before being acquired. That matters because H1’s model depends on building structured information products, not just shipping a pretty interface. Katz had already shown he could organize messy institutional data into something customers would actually pay for.

Traction, product expansion, and the shape of the business

H1 looks a lot less like a small startup now than it did during its Y Combinator days. The company has more than 300 employees, customers across 6 continents, and over 200 customers. It also has 6 of the top 20 pharma companies as customers, and after its Veda acquisition it now powers 9 of the top 10 health plans in America. Earlier reporting pegged H1’s data network at more than 10 million healthcare professionals.

H1 has also used acquisitions as a way to get broader, not just bigger. It bought Ribbon Health to expand into health-plan and digital-health provider data. Then it bought Veda to deepen payer-side capabilities like rosters and network management. That’s a clear signal that H1 wants to own more of the provider-data stack, especially on the payer side where directory accuracy is both operationally painful and commercially valuable.

Fundraising and competition

The new round is $40 million, and CVS Health Ventures led it. That came after H1 had already turned cash-flow and EBITDA profitable in 2025 and while management was forecasting growth of more than 40% for 2026. Katz told TechCrunch the company wasn’t actively looking to raise, which makes this feel more like a strategic partnership round than a rescue. H1’s last disclosed valuation was $750 million, set when Altimeter Capital led a $100 million round in November 2021.

Competition is real, even if it’s not flashy. Definitive Healthcare is the most obvious public comp in healthcare commercial intelligence, and big incumbents like IQVIA have long sold data-heavy products into life sciences and provider organizations. The older alternative is even tougher to kill: internal teams stitching together public records, third-party files, CRM notes, and lots of manual checking. H1’s differentiation is that it spans clinical, medical, commercial, and payer workflows with one data foundation. That’s why Katz argues, “If you’re a workflow SaaS company, you could vibe code that.”

Why are investors backing the H1 healthcare data platform now?

This round matters because it says something specific about what investors still want. H1 didn’t raise on a “we have AI” story alone. It raised after getting profitable, after building a large customer base, and after proving it could widen its footprint through acquisitions. In a market where lots of pre-2022 software companies are getting treated like leftovers, that’s a real signal.

CVS is also not a tourist investor. CVS Health Ventures was launched with $100 million to back companies that can make healthcare more accessible, affordable, and simpler, and H1 now sits right in the middle of provider data, payer operations, and digital navigation. If CVS ends up becoming more than a cap-table partner — say, a distribution or product partner across Aetna-aligned workflows — this round could matter more than its size suggests.

There’s a second message here. Katz’s other line from the TechCrunch interview was, “I don’t worry about Claude ever doing what we do.” That sounds a little self-serving. It’s also not crazy. The interface layer in software is getting cheaper fast. But proprietary, normalized healthcare data that works across pharma, trials, and insurance is still expensive to build and even harder to maintain.

How big is the market for healthcare data platforms?

The category is large enough that H1 doesn’t need to own all of it to build a big company. IMARC estimates the U.S. healthcare big data analytics market was worth $24.71 billion in 2025 and projects it will reach $62.43 billion by 2034. Grand View Research, looking at U.S. healthcare business intelligence, expects a 13.3% CAGR from 2025 to 2030. Those aren’t niche-software numbers. They describe a big, still-expanding budget line inside healthcare.

Because more healthcare decisions are becoming data problems, the timing makes sense. Clinical trial teams want faster site selection and better patient representation. Medical affairs groups want better KOL mapping. Health plans need cleaner provider directories and stronger network data. And AI only increases the value of dependable underlying data — if the source layer is wrong, the fancy model on top just produces faster nonsense. Interoperability pressure, cloud adoption, and broader digitization across health systems all push buyers toward platforms that can normalize messy data.

What comes next for H1 healthcare data platform?

H1 isn’t selling a dream of replacing healthcare with AI magic. It’s selling the less sexy claim that accurate doctor and provider data is still hard to build, hard to maintain, and worth real money. That’s a much better business argument. For the H1 healthcare data platform, the next thing to watch isn’t just revenue growth — it’s whether the CVS relationship turns into deeper payer distribution and whether H1 can keep turning acquisitions into one coherent product stack.

Read how Corgi raised a $106M Series B1 at a $2.6B valuation to rebuild startup insurance with AI-native underwriting, same-day coverage, and software-first workflows.

FAQ

– What funding did H1 just raise?  

 H1 raised $40 million in a round led by CVS Health Ventures in May 2026. What makes the round interesting is that H1 said it wasn’t out shopping for capital — the company was already cash-flow and EBITDA profitable in 2025, which makes this look more strategic than defensive.

– How does H1’s platform actually work?  

 H1 works by aggregating doctor, clinical, scientific, and provider data into one searchable system that customers can use for specific healthcare workflows. A pharma team might use it to identify key opinion leaders or trial investigators. A health plan might use it to clean up provider directories, manage rosters, or improve network data.

– Who founded H1?  

 H1 was founded in 2017 by Ariel Katz and Ian Sax. Katz had already built one startup before H1 — ResearchConnection — which grew to more than 40 universities, giving him a real track record in turning messy information problems into software products.

– What market is H1 competing in?  

 H1 sits in the healthcare data, healthcare analytics, and commercial intelligence category, with overlap into provider data management for payers. That puts it up against specialist data vendors and broader healthcare intelligence incumbents. It also faces the oldest competitor of all: internal teams still relying on fragmented files, public records, and manual verification.

Corgi is an AI-native insurance carrier that sells startup coverage without the usual broker maze and weekslong underwriting drag. The Corgi insurance startup just announced a $106 million Series B1 at a $2.6 billion valuation, only 3 weeks after a $160 million Series B valued it at $1.3 billion. That kind of jump is rare even by 2026 venture standards. Founded in 2024 by Emily Yuan and Nico Laqua in San Francisco, Corgi is betting that founders will buy insurance faster if the product actually feels like software.

The core problem is simple. Startups need coverage early for fundraising, hiring, leases, enterprise contracts, and compliance, but the old process is slow and fragmented. It’s built around brokers and carriers that don’t really understand fast-changing tech risk.

What is the Corgi insurance startup and how does it work?

Here’s the clean version: a founder fills out Corgi’s online application, gets quoted in minutes, and can often bind coverage the same day. Most applications take under 5 minutes. The buying flow runs through an app and dashboard rather than email chains and callbacks.

The product is organized by startup stage. Pre-seed and seed customers get core bundles around CGL and D&O. Tech E&O and cyber are part of that mix too. Series A companies add media and EPLI. Growth-stage customers can layer on fiduciary coverage. The platform also offers add-on lines like crime, hired and non-owned auto, and representations and warranties.

More interesting is the AI-liability angle. Laqua said Corgi is building coverage for newer categories of risk, including cases where an AI system leads to financial loss, misinformation, operational failures, or compliance trouble. Older policies often treat those exposures vaguely. Some exclude them outright.

Corgi keeps hammering one message: it’s a full-stack carrier, not just a slick front end. The company handles underwriting and claims. It offers modular coverage by company stage, and replaces a traditional 2-4 week underwriting cycle with instant quotes and same-day binding. That’s a very different pitch from a normal brokerage workflow.

Who founded the Corgi insurance startup and why?

The founding story

Corgi was started in 2024 by Nico Laqua and Emily Yuan after the pair ran into insurance friction at their previous company, Basket Entertainment. Laqua has described one episode where a slow quote nearly put an important contract at risk, and another where an insurer denied a copyright-related claim he thought should have been covered. That wasn’t abstract founder pain. It turned into the company.

The startup joined Y Combinator’s Summer 2024 batch soon after launch. It helps explain how fast Corgi moved from idea to distribution, fundraising, and customer access.

Why these founders had market fit

Yuan and Laqua weren’t insurance lifers. But they had already built and scaled internet products at serious volume. Forbes’ 2024 profile on their earlier company says Yuan dropped out of Stanford in 2020 to build Picnic, a Gen Z social app that later pivoted into Basket Entertainment, where she worked with Laqua.

That earlier business wasn’t tiny. Basket had more than 35 games and 150 million monthly users. It also had $6 million in year-to-date revenue in 2023, while working with brands including Barbie and Marvel. Yuan and Laqua were also named to Forbes 30 Under 30 in 2024 for Basket. So even if insurance looks like a hard left turn, the pair already knew how to build, distribute, and sell into fast-moving digital markets.

Early traction, fundraising, and the awkward valuation question

Corgi’s live product is already in market, and TechCrunch said the company counts Deel and Artisan as customers. It raised a $108 million Series A 4 months before this latest round, then a $160 million Series B at a $1.3 billion valuation on May 6, 2026, and now a $106 million Series B1 at $2.6 billion. Total funding is now $378 million.

That sequence is the whole story. A startup doubling its valuation in 3 weeks — with the same investor set involved across the back-to-back rounds — is unusual enough that TechCrunch’s reporting focused as much on venture accounting as on the company itself. One LP told the outlet there’s “growing distrust of internal markups.” Kindred’s Kanyi Maqubela pushed back, saying “LPs really like exits above all,” and argued revenue growth justified the move.

The investor list around Corgi includes Kindred Ventures, Prime Capital, Leblon Capital, Alumni Ventures, Y Combinator, and TCV. TCV led the earlier Series B. TechCrunch also noted that its original headline on the B1 story misstated the valuation and was later corrected.

How Corgi compares with Vouch, Embroker, and legacy insurance

Corgi isn’t entering an empty market. Vouch already sells startup-focused business insurance and frames itself as a broker for ambitious companies. Embroker has been selling digital startup insurance since 2015. It built one of the better-known online programs for high-growth tech businesses.

Corgi’s pitch is tighter vertical focus and more control. It’s a full-stack carrier with in-house claims handling and AI-driven underwriting. Same-day binding is part of the pitch too. It also sells stage-specific packages that match how startups actually buy insurance. Legacy brokers still win on relationships and breadth. Corgi is selling speed, simpler packaging, and policy language that tries to keep up with AI-era risks.

Why did the Corgi insurance startup raise $106M so fast?

Because insurance eats capital.

Laqua called it a “highly capital-intensive industry,” and that’s not spin. If Corgi wants to move beyond a narrow startup bundle into more commercial lines, expand embedded distribution, and keep building underwriting systems and claims operations, it needs a lot more balance-sheet muscle than a normal SaaS company would.

The fresh money is earmarked for 4 things: entering new insurance categories and scaling the AI underwriting platform. It also plans to grow embedded partnerships and hire. That tells you the company thinks its wedge is real and now wants range — not just more of the same D&O and cyber business.

But the financing also raises the pressure. A paper markup this fast can look incredible on a dashboard. It also creates a very public expectation that Corgi will turn speed into durable underwriting performance, not just fast fundraising. If that doesn’t happen, the LP skepticism won’t go away.

How big is the market for Corgi’s insurance model?

Big enough that investors will tolerate some weirdness. The U.S. insurance industry wrote $1.7 trillion in net premiums in 2024, according to the Insurance Information Institute. That’s the backdrop for why founders keep trying to rebuild slices of insurance with software.

Corgi’s nearer-term opening is smaller but still huge. One market forecast pegs the global cyber insurance market at $16.54 billion in 2025 and $32.19 billion by 2030, a 14.2% compound annual growth rate. And cyber is only one piece of what Corgi sells.

A structural shift is helping companies like this. Commercial insurance is getting more segmented by company size and product type. Risk profile matters more too. Startup buyers increasingly need policies tied to vendor security reviews, board requirements, and AI-related exposure.

What should investors watch next at Corgi?

The easy headline is the valuation jump.

The harder question is whether the Corgi insurance startup can turn that jump into something sturdier: more customers like Deel and broader product lines. Faster claims handling matters too. So does evidence that AI underwriting is improving economics rather than just compressing sales cycles.

Read how Anthropic raised a $65B funding round at a $965B valuation to expand Claude’s enterprise AI platform with stronger coding agents, agentic workflows, and safety-focused large language models.

FAQ

– What funding did Corgi raise in May 2026? 

 Corgi raised $106 million in a Series B1 announced on May 28, 2026, at a $2.6 billion valuation. That came just 3 weeks after its $160 million Series B at a $1.3 billion valuation and 4 months after a $108 million Series A, bringing total funding to $378 million.

– How does Corgi’s startup insurance platform work? 

 Corgi runs a digital insurance flow built for tech companies, where founders can apply online, get quoted in minutes, and often bind coverage the same day. It sells stage-based packages for pre-seed, Series A, and growth companies. Customers can also add policies like cyber, Tech E&O, D&O, EPLI, and fiduciary coverage from the same platform.

– Who are the founders of Corgi? 

 Corgi was founded in 2024 by Emily Yuan and Nico Laqua. Before that, they built Picnic, which evolved into Basket Entertainment — a gaming business that had 35+ titles and 150 million monthly users. It also had $6 million in 2023 revenue, and helped land the pair on Forbes’ 30 Under 30 list in 2024.

– Is Corgi a broker or an insurance carrier? 

 Corgi presents itself as a full-stack insurance carrier, which is a big part of how it distinguishes itself from startup-insurance brokers. That means it controls more of the underwriting and claims experience directly, instead of only acting as a distribution layer between founders and outside carriers.

Anthropic builds large language models and enterprise AI tools, and this Anthropic funding round is massive even by 2026 standards: $65 billion at a $965 billion post-money valuation. The core problem it’s chasing is simple — big companies want AI that can write code and run agentic workflows, while staying honest enough to trust in production. Founded in 2021 by siblings Dario Amodei and Daniela Amodei, Anthropic now looks like it may be heading into its final private raise before testing public markets.

That alone is huge.

But the timing matters more than the headline number. Anthropic announced the round the same day it launched Claude Opus 4.8, a new model pitched around stronger agentic work and better coding, with a bigger emphasis on honesty and self-correction. It also plans to put some of the money into safety and interpretability research. More will go to compute capacity and the partnerships customers already depend on.

What is Anthropic and how does Claude work?

Anthropic is a frontier AI company whose flagship product, Claude, is sold as a family of models and tools for coding, reasoning, document work, research, and enterprise automation. In practical terms, a customer can use Claude through chat or the API. They can also use Claude Code — Anthropic’s coding agent that works inside a developer workflow and can inspect a codebase, plan changes, edit files, run tasks, and help ship code faster.

Claude Code is where a lot of the current enterprise pull comes from. Anthropic describes it as a terminal-native agentic tool that can build features from plain-English instructions and debug issues by tracing root causes through a repository. It can even create commits and pull requests directly with git. That’s a lot closer to a junior engineer with repo access than a chatbot in a browser tab.

With Opus 4.8, Anthropic pushed that workflow further. The model now supports dynamic workflows in research preview, which let Claude plan work and run hundreds of parallel subagents in a single session. It can verify outputs and report back. Anthropic says Claude Code with Opus 4.8 can handle codebase-scale migrations across hundreds of thousands of lines of code from kickoff to merge. That’s exactly the kind of pitch enterprise buyers want to hear when they’re deciding whether AI can move from toy to tool.

The before-and-after difference is pretty obvious. Before this kind of setup, teams had to bounce between chat windows, ticketing systems, IDEs, and humans doing manual code review and repo spelunking. After it, Claude can analyze a large codebase and keep context cleaner with specialized subagents. It can also draft a plan before editing disk files, then automate repetitive chores engineers hate — tests, lint fixes, dependency updates, release notes, and PR scaffolding.

Who founded Anthropic and why did they leave OpenAI?

Anthropic was founded in 2021 by Dario Amodei and Daniela Amodei, along with other former senior OpenAI figures including Jack Clark, Jared Kaplan, Sam McCandlish, Tom Brown, and Chris Olah. The company started with a safety-first pitch: build highly capable models, but spend just as much effort making them steerable, interpretable, and reliable. That framing wasn’t random. It came straight out of a split over how fast frontier labs should commercialize powerful AI systems.

The founders had obvious market fit

Dario wasn’t an outsider showing up late to AI. He worked at Google Brain, then became OpenAI’s vice president of research, where he helped shape major model-scaling work. Daniela came from Stripe and then OpenAI, where she ran safety and policy work before co-founding Anthropic and taking the president role. If you were sketching the ideal résumé for an AI lab that wants to sell power and caution at the same time, it would look a lot like that sibling pairing.

Their early execution already looked different

Anthropic’s first public funding announcement in May 2021 raised $124 million. Even then, the company framed itself less like a consumer app company and more like a research-heavy lab focused on reliability and human feedback. It also focused on interpretability and steerability. The early team’s prior work touched GPT-3, scaling laws, multimodal neurons, and AI safety research, which gave Anthropic credibility with investors long before Claude became a brand enterprises recognized.

Traction is now doing a lot of the talking

Anthropic’s run-rate revenue crossed $47 billion earlier this month and it expects a 130% revenue jump to reach its first operating profit. It also points to stronger enterprise growth tied to Claude Code. Separately, Anthropic serves more than 300,000 business customers. Its large-account base — customers worth more than $100,000 in run-rate revenue each — grew nearly 7x over the past year.

The fundraising details are almost absurd

This Series H round was co-led by Altimeter Capital, Dragoneer, Greenoaks, Sequoia Capital, Capital Group, Coatue, and D1 Capital Partners. Baillie Gifford, Blackstone, Brookfield, D.E. Shaw Ventures, DST Global, and Fidelity Management & Research also participated. Strategic partners Samsung, SK Hynix, and Micron joined too. And $15 billion of the round came from previously committed hyperscaler investments, including $5 billion from Amazon announced in April.

One detail says a lot about the frenzy: last month, TechCrunch reported Anthropic was nearing a $50 billion raise, and one institutional investor had offered as much as $5 billion just to get a meeting with CFO Krishna Rao.

Anthropic’s competition is real — and expensive

OpenAI is the clearest comparison because it’s chasing the same buyers and the same talent. Eventually, it will be after the same public-market attention too. OpenAI disclosed a $122 billion funding round in March 2026 at an $852 billion post-money valuation, which means Anthropic is competing against a rival with enormous capital, huge distribution, and a much bigger consumer footprint.

But Anthropic isn’t trying to out-ChatGPT ChatGPT. Its sharper position is enterprise reliability, coding, and safety-flavored model behavior. That matters because the real incumbent alternative for a lot of companies still isn’t another AI startup. It’s internal engineering teams, messy software stacks, outsourced services, and a pile of manual workflow glue that nobody enjoys maintaining.

Then there’s xAI folded into Musk’s broader orbit. SpaceX, after merging with xAI earlier this year, is targeting a $2 trillion valuation in a pending IPO while seeking more than $75 billion. That turns the fight into something bigger than model quality. It’s now a contest over compute and chips. Distribution too. And who can look least reckless while scaling all of it.

Why does this Anthropic funding matter?

Because this round doesn’t just buy time. It buys options.

Anthropic plans to use the cash to “advance our safety and interpretability research, expand compute to meet growing demand for Claude, and scale the products and partnerships” customers already use. That’s a roadmap, not a slogan. Safety work is expensive. Compute is brutally expensive. Enterprise AI customers don’t care how elegant your research is if the model can’t stay available, fast, and useful under heavy demand.

The same-day Opus 4.8 launch makes the funding story more concrete. Anthropic is trying to prove it can ship better models while holding onto its trust-and-control narrative. It’s also preparing a broader release of models with capabilities on par with Mythos, its more tightly controlled cybersecurity model, once stronger safeguards are in place. That’s a tricky balancing act. Shipping faster helps revenue. Shipping too fast can wreck the whole brand if the “honest and self-correcting” pitch stops feeling true.

For investors, the thesis is pretty plain. If Claude keeps winning inside enterprise software teams — especially with coding and agent workflows — Anthropic could become one of the few AI companies that looks like both a frontier lab and an operating business.

How big is the market behind Anthropic funding?

It’s big enough to justify wild numbers, even if the private-market enthusiasm still feels overheated. Grand View Research estimated the global enterprise generative AI market at $2.94 billion in 2024 and projects it to reach $19.81 billion by 2030, a 38.4% compound annual growth rate. North America accounted for 41% of that market in 2024, which helps explain why U.S.-based enterprise AI vendors keep attracting giant checks.

There’s also a narrower model-market angle. Gartner forecast the worldwide generative AI models market would grow 149.8% in 2025 to more than $14 billion. That’s the structural tailwind behind the whole race: model builders aren’t just selling access to chat interfaces anymore. They’re selling core infrastructure for software development and internal operations. Customer service too. Research and security as well.

That’s why Anthropic’s timing makes sense. Enterprises finally care less about novelty and more about whether AI can fit into existing workflows, respect permissions, stay governable, and produce work someone can actually ship. Claude Code, subagents, plan mode, and long-running orchestrated workflows line up neatly with that shift.

What should you watch after Anthropic funding?

The obvious number is the $65 billion raise. The more interesting question is whether Anthropic can turn that capital into durable enterprise behavior before an IPO window opens.

This Anthropic funding round says the market believes Claude can be more than a strong model. Investors are betting Anthropic might become one of the few AI companies with enough product depth and safety credibility to survive the post-hype shakeout. Customer demand is part of that case too. The next thing to watch isn’t another flashy demo. It’s whether Claude keeps showing up deeper inside real software teams — and whether Anthropic can keep that momentum without losing the caution that made it different in the first place.

Read how C2i Semiconductors raised a $16.7M Series A led by Peak XV Partners and backed by TDK Ventures to build software-defined power delivery chips that improve efficiency and thermal performance in AI servers.

FAQ

– What happened in Anthropic’s latest funding round?  

 Anthropic raised $65 billion in a Series H round at a $965 billion post-money valuation. The raise was co-led by major crossover and venture investors including Altimeter, Dragoneer, Greenoaks, Sequoia, Capital Group, Coatue, and D1, and it may be the company’s last private round before a public listing.

– How does Claude actually work for enterprise customers?  

 Claude works through chat, APIs, and Anthropic’s coding product Claude Code, which can inspect repositories, plan edits, write code, run multi-step workflows, and help create pull requests. With Opus 4.8, Anthropic added dynamic workflows and stronger support for parallel subagents, pushing Claude closer to an agentic software teammate than a simple assistant.

– Who founded Anthropic?  

 Anthropic was founded in 2021 by siblings Dario Amodei and Daniela Amodei with several other former OpenAI researchers and executives. Dario previously led research at OpenAI, while Daniela held senior safety and policy roles, which is a big reason Anthropic has always leaned so hard into reliability and AI safety as part of its identity.

– What market is Anthropic competing in?  

 Anthropic sits in the frontier AI and enterprise generative AI market, where labs are competing to sell models and agent tools to businesses, developers, and large institutions. One useful benchmark: the enterprise generative AI market was estimated at $2.94 billion in 2024 and is projected to reach $19.81 billion by 2030, which helps explain why investors are still writing giant checks despite the risk.

C2i Semiconductors builds power delivery chips and control systems for AI servers. The latest C2i Semiconductors funding update takes its Series A to $16.7 million after TDK Ventures added fresh capital to the round on May 28, 2026, a few months after Peak XV Partners led the original $15 million close in February. The startup is chasing a hard infrastructure problem: AI racks keep getting denser, but moving electricity efficiently from the grid to the GPU core still wastes power, creates heat, and can even hurt compute performance. Founded in 2024 by Ramprasad Ananthaswamy — better known as Ram Anant — with Preetam Charan Anand Tadeparthy and Vikram Gakhar, the Bengaluru company is trying to rebuild that power stack from the ground up.

What does C2i Semiconductors actually build?

C2i is building a software-defined voltage regulator platform for AI and high-performance computing systems. In practical terms, that means designing the silicon and control logic that takes power coming into a server platform and turns it into tightly regulated, low-voltage power that advanced processors can actually use. Its first-generation chip focuses on the last stage of that chain — the step that takes board-level power down to the sub-1-volt rails used by GPUs and accelerators. The longer roadmap stretches across the full “grid-to-core” path.

Here’s the workflow C2i is targeting. Today, a lot of AI server designs still rely on a multi-stage conversion path: roughly 400V to 48V, then to 12V or 6V, then down again to processor core voltage. C2i says that final stage is where huge current, board losses, and control latency start to bite. Its architecture uses proprietary control and power-conversion IP to cut stages where it can. It also switches faster and keeps regulation tighter as GPU loads jump between sleep and full-throttle modes.

That matters because old-school designs pile on regulators and inductors. Routing complexity and heat follow. C2i’s pitch is that a processor-agnostic platform can scale from about 100W systems to several kilowatts, fit into tighter board real estate, and deliver better thermal behavior without locking the customer into one compute vendor. The founders say those design choices can translate into around 10% more queries per watt at the system level, with longer server life as a side effect. Ambitious? Definitely. But that’s the level of improvement hyperscalers care about.

Who founded C2i Semiconductors and why?

The founding story

C2i started in 2024 in Bengaluru, and the name is short for conversion, control, and intelligence. That’s not just branding fluff. It’s basically the company’s thesis: power electronics for AI infrastructure shouldn’t be treated as a pile of isolated components. They should work as one coordinated system spanning conversion, regulation, and embedded intelligence. The founders set out to build a product-led semiconductor company from India for global data center and AI infrastructure customers, not another engineering services outfit.

Why this team fits the problem

This isn’t a first-time hardware team learning on the fly. Ram Anant is founder and CEO, with 35 years in power semiconductor systems and technical management. Preetam Tadeparthy, the CTO and VP of engineering, brings 24 years in mixed-signal design and system architecture plus 70+ US patents. Vikram Gakhar, who leads mixed-signal work, has 24 years in analog and control-loop design and 16+ US patents. Across the leadership group, C2i has more than 100 years of combined semiconductor experience and over 100 US patents. ET also described the company as the brainchild of former Texas Instruments executives.

Early signals from the company

The clearest recent proof point came on May 28, 2026, when C2i taped out its smart power stage chip for AI infrastructure. That matters because tape-out is the moment a chip design is finalized and sent to the fab for manufacturing. In other words, the company has moved from architecture talk into actual silicon execution. The chip was designed end-to-end in India. For a fabless startup targeting a hard semiconductor problem, that stands out.

There are other signs the company isn’t just building in a vacuum. The founders say they’ve filed 9 patents so far, with more on the way. They’ve also said they’re in discussions with 3 to 4 enterprise server customers on next-generation platforms. One product is being manufactured at Tower Semiconductor, while another is planned at GlobalFoundries. It’s still early. But for a 2024 startup, it’s more concrete than a lot of deeptech pitch decks ever get.

C2i Semiconductors funding and market position

The money has come in stages. C2i raised $4 million from Yali Capital in November 2024. Then it closed a $15 million Series A in February 2026 led by Peak XV Partners, with participation from TDK Ventures and Yali Capital. On May 28, 2026, TDK Ventures added more capital in an extension that brought the full round to $16.7 million. The stated use of funds is straightforward: speed up development of high-density, ultra-reliable power delivery systems for AI computing.

Competition is where the story gets interesting. Legacy server power still leans hard on conventional 12V multi-phase regulator architectures, which get bulky and lossy as current rises. Vicor attacks that problem with factorized power architecture and power-on-package approaches that move conversion closer to the processor. That reduces “last-inch” losses on AI accelerator cards. Monolithic Power Systems is pushing its own AI server modules and says it already has 100+ AI power products, with a target of 120 kW-per-rack solutions by 2027. C2i’s bet is different: a software-defined, processor-agnostic platform that spans more of the stack instead of selling only a point solution. That broader system view is probably what Peak XV and TDK are paying for.

Why does this C2i Semiconductors funding round matter?

Timing. That’s the whole thing.

An extension round landing right as the company announces a tape-out is exactly the kind of sequencing you want in semiconductors. Designing a chip is expensive. Validating first silicon, fixing whatever comes back broken, packaging it, building reference boards, and getting customers comfortable enough to design it into servers is where a lot of startups burn cash. This round gives C2i a better shot at surviving that awkward middle stretch between prototype and production.

It also supports the company’s push beyond India. The founders have said they want a US office to stay close to customers and decision-makers. Then they want a Taiwan applications and systems engineering team to work with ODMs and protect design wins. That isn’t optional in this part of the chip business. AI power silicon doesn’t sell like software. It gets sold through painstaking customer engagement and board-level validation. Then come the multi-year platform cycles.

Investor mix matters here too. Peak XV brings venture scale. Yali has deeptech focus. TDK adds something more tactical — real power and component expertise. A follow-on check from an existing semiconductor investor usually means the company hit enough technical and commercial milestones to justify more capital.

How big is the AI data center power market?

Pretty big already. And still getting bigger.

One useful benchmark: the global data center power market was estimated at $22.77 billion in 2025 and is projected to reach $71.76 billion by 2033, with a 15.7% CAGR from 2026 to 2033. The core driver is simple — hyperscale, cloud, and AI workloads keep pushing power density higher. That forces operators to rethink UPS systems, distribution, monitoring, and board-level power conversion. C2i is going after a narrower slice than that total market, but it sits inside a category that’s expanding fast.

India’s setup helps too. Yali notes that about 20% of the global chip design workforce is in India, and C2i is trying to turn that talent base into a globally relevant fabless company. At the policy level, the Indian government has been leaning harder into semiconductor design and manufacturing through India Semiconductor Mission 2.0 and the Design Linked Incentive program. The DLI scheme currently supports 24 startups, with a target of enabling at least 50 fabless semiconductor companies in the next phase.

Capital is starting to follow that shift. Indian semiconductor startups raised about $50 million in 2025, up from more than $28 million in 2024, based on Inc42’s startup trends report cited in the source material. Recent deals for companies like Sophrosyne Technologies and Morphing Machines show that investors are willing to back hard-tech businesses before they become revenue machines. It’s still a small market by global standards. But it’s no longer fringe.

Where could C2i Semiconductors go next?

C2i isn’t interesting because it raised money. Plenty of startups do that.

It’s interesting because C2i Semiconductors funding is now tied to a real technical milestone, a very specific AI infrastructure bottleneck, and a founding team that looks built for the job. The next thing to watch is brutally practical: whether the taped-out chip comes back clean, whether customer evaluations turn into design wins, and whether C2i can move from smart architecture story to shipping semiconductor product.

Read how Thea Energy raised a $100M Series B led by Thomas Tull’s U.S. Innovative Technology Fund to build software-controlled stellarator fusion reactors using flat superconducting magnets instead of complex twisted coils.

FAQ

– What is the latest C2i Semiconductors funding update? 

 The latest update is that C2i’s Series A has reached $16.7 million as of May 28, 2026. The round was first announced at $15 million in February 2026 with Peak XV Partners as lead investor, and TDK Ventures later extended the round with fresh capital.

– How does C2i Semiconductors’ product work for AI servers? 

 C2i builds power delivery silicon and control software that help convert incoming server power into the tightly regulated, very low-voltage rails used by AI processors. Its first chip targets the final conversion stage near the GPU, where current is huge and board losses are painful. Better control can improve efficiency and thermal performance.

– Who founded C2i Semiconductors? 

 C2i was founded in 2024 by Ramprasad Ananthaswamy, also known as Ram Anant, together with Preetam Charan Anand Tadeparthy and Vikram Gakhar. The leadership team brings decades of power semiconductor and mixed-signal design experience, and official company material lists more than 100 combined years in the field.

– Is C2i Semiconductors an AI company or a semiconductor company? 

 It’s a semiconductor company serving the AI infrastructure market. More specifically, it’s building power management and voltage regulation technology for AI data centers and high-performance computing systems, which puts it in the fabless semiconductor category with an AI infrastructure focus.

Thea Energy is a New Jersey fusion company building stellarator reactors with software-controlled flat magnets instead of the twisted coil systems that have made stellarators brutally hard to manufacture. The startup has now raised an oversubscribed $100 million Series B led by Thomas Tull’s U.S. Innovative Technology Fund, a round that pushes it into the better-funded tier of private fusion companies. That matters because fusion doesn’t usually fail on ambition. It fails when exotic physics runs into impossible hardware, cost, and maintenance demands. Thea was founded in 2022 by Brian Berzin, David Gates, and Matt Miller, and the company’s pitch is that smarter magnet architecture might finally make stellarators practical enough to leave the lab.

What does Thea Energy actually build?

Thea Energy builds a planar-coil stellarator. In plain English, it uses arrays of high-temperature superconducting flat magnets and software controls to create the 3D magnetic fields needed to confine plasma. It does that without relying on the famously awkward custom-shaped modular coils that define older stellarator designs. That shift moves complexity out of hardware and into software. A big deal if you’re trying to build lots of identical parts instead of one-off precision sculptures.

Its first major machine is Eos, which Thea describes as a “power plant relevant” integrated demonstration system. Eos is designed as a deuterium-deuterium neutron source that can run in steady state and produce isotopes, including tritium and medical radioisotopes. It also gives the company a way to prove its core architecture on something much closer to a commercial plant than a science experiment. Helios is the follow-on commercial power plant.

What stands out here isn’t just the magnets. It’s the control layer. Thea says the system can optimize operating points in real time and correct for changing conditions. It also keeps the machine adaptable instead of locked into one fixed geometry. That’s a sharp contrast with classic stellarators, where a lot of the performance is baked into hard-to-change 3D coil shapes from day 1.

Maintenance is part of the pitch too. Thea’s geometry is supposed to allow sector-based access, so operators can remove large sections for service with less downtime than older stellarator concepts. One small but important wrinkle: early Thea designs talked about 12 encircling magnets, but later versions dropped that feature. The current story is less about a fixed outer ring and more about programmable planar field control.

Who founded Thea Energy and why does it matter?

The founding story

Thea Energy came out of Princeton Plasma Physics Laboratory and Princeton University work on magnet-array-based stellarator designs. David Gates developed the underlying stellarator magnet array technology at PPPL through the ARPA-E BETHE program, and the company spun out in 2022 to commercialize that research. That origin matters because Thea isn’t trying to invent an entirely new confinement concept from scratch. It’s taking a known fusion path and trying to make it buildable.

Why this founding team has real market fit

Brian Berzin brings the commercialization angle. He previously served as VP of Strategy at General Fusion and also has experience in venture capital, growth equity, private equity, and electrical engineering startups. That’s useful because fusion startups don’t just need plasma talent. They need people who understand fundraising and industrial partnerships. They also need people who know how hardware companies die when capital planning goes sideways.

Gates brings the scientific credibility. He has 30+ years in fusion research across stellarators and tokamaks, served as head of advanced projects at PPPL, held a senior research role at Princeton, and had produced 200+ publications with 7,500+ citations by 2025. If Berzin is the bridge to the market, Gates is the reason investors can take the engineering thesis seriously.

Traction, fundraising, and the current roadmap

Thea announced its latest raise on May 27, 2026. USIT led the $100 million Series B, with participation from General Innovation Capital Partners, Linse Capital, Calm Ventures, Climate Capital, Divergent Capital, Emerald Technology Ventures, Gaingels, Idemitsu Kosan, Overlay Capital, Timescale Ventures, and What If Ventures. The company had already raised a $20 million Series A, and the new round brings total private investment to $130 million, according to the source article.

The money is earmarked for expanding magnet manufacturing and starting construction of Eos next year. By early 2026, Thea had also won DOE certification for its Helios preconceptual design, said it was talking with 5 states about siting Eos, and described itself as an 80+ person team of engineers, scientists, and commercialization staff. The public target is ambitious: complete Eos in 2030, then bring the Helios commercial plant online in 2034.

How Thea Energy compares with other fusion startups

The obvious benchmark is Commonwealth Fusion Systems. CFS is following the tokamak route and plans to use new capital to finish SPARC. It also wants to advance its first ARC plant in Virginia, and now says it has raised $3 billion in total. That’s a completely different scale from Thea. It shows how hard it is for any new fusion company to stay relevant without a credible manufacturing shortcut.

Type One Energy is a closer conceptual comparison because it’s also pursuing a stellarator. In January 2026, TechCrunch reported that Type One had raised an $87 million convertible note, bringing its total venture backing to more than $160 million, though its business model leans more toward selling core technology to utilities and power providers. Thea’s distinction is the planar-coil, software-heavy architecture. Simpler parts. More configurability. A maintenance story that’s easier to explain to plant operators.

There’s also the legacy comparison. Traditional stellarator alternatives lean on extremely complex 3D magnetic coil sets that are difficult to build, align, and service. Thea is betting investors will back software-defined field shaping and repeatable magnet manufacturing over bespoke machine craftsmanship.

Why Thea Energy’s $100M round matters

This round matters because it shifts Thea from “interesting reactor concept” toward “actual industrial build program.” Expanding magnet manufacturing is a very different milestone from publishing papers or running bench tests. It means the company now has to prove that its simplification story survives contact with real production tolerances, real supply chains, and real schedules.

Eos is also a smart midpoint if Thea can execute. A neutron-source system that can run in steady state and produce useful isotopes gives the company something closer to an interim commercial path while de-risking the Helios architecture. That’s a lot more believable than promising grid power first and figuring out revenue later.

But let’s be honest: $100 million is big for a young fusion startup, not big for fusion full stop. The round buys Thea time and hardware progress. It also buys talent. It doesn’t buy certainty. The company still has to show that its programmable magnet thesis works at scale, not just in prototypes and design packages.

Is fusion finally becoming a real market?

Fusion still isn’t a market in the conventional sense. It’s a race to make one. But the structure around it is getting more real. The U.S. Department of Energy’s current fusion roadmap is explicitly aimed at accelerating commercialization by the mid-2030s and scaling the domestic private fusion sector in the 2030s.

Money has followed that shift. In the Fusion Industry Association’s 2023 industry report, private fusion companies had attracted more than $6 billion in investment, up $1.4 billion year over year, and the U.S. alone counted 25 private fusion companies. That doesn’t mean fusion is solved. It does mean investors, governments, and power-hungry industries are treating it less like science fiction and more like a manufacturing challenge with a clock on it.

That timing helps Thea. Not because fusion got easier overnight, but because grid demand is changing what capital wants. Baseload, carbon-free power is suddenly a very hot word again. A startup that can argue for lower capital cost and simpler maintenance will get a longer hearing now than it would have 5 years ago. Software-tunable hardware helps too.

Thea Energy outlook

Thea Energy now has real money, a differentiated stellarator thesis, and a clearer path to its first serious machine. That’s enough to make it one of the more credible second-tier fusion bets in the U.S., though still far behind the capital base of the category’s biggest names. The next thing to watch isn’t another concept rendering. It’s whether Eos construction actually starts in 2027 and whether Thea can show that its magnet architecture scales from smart idea to reliable hardware.

Read how Triomics raised $22M in Series B funding to use oncology-focused AI for clinical trial matching, chart prep, and cancer registry workflows.

FAQ

– What was Thea Energy’s latest funding round?  

 Thea Energy raised an oversubscribed $100 million Series B on May 27, 2026. USIT led the round, and the cash is meant to expand magnet manufacturing and push Eos into construction.

– How does Thea Energy’s fusion reactor work?  

 Thea is building a stellarator that uses software-controlled planar HTS magnets to shape the magnetic field around plasma. The idea is to replace much of the hard-to-manufacture 3D coil complexity of older stellarators with flatter, more repeatable components. A control stack can tune the field in real time.

– How did Thea Energy’s founders get into fusion?  

 The company’s leadership blends lab science with fusion commercialization. Brian Berzin came from General Fusion and finance-backed startup work, while David Gates spent decades in fusion research at PPPL and Princeton before spinning the core technology into Thea in 2022.

– Is Thea Energy a tokamak or a stellarator company?  

 Thea Energy is a stellarator company, not a tokamak company. That matters because stellarators are known for steady-state stability, but they’ve historically been dragged down by magnet complexity. That’s the problem Thea is trying to solve with its planar-coil architecture.

Triomics builds software that uses oncology-specific AI to read messy cancer records and automate work like clinical trial matching, chart prep, and registry reporting. The oncology AI startup has now raised $22 million in Series B funding. Battery Ventures led the round, with returning backers Nexus Venture Partners, Lightspeed, Y Combinator, and others joining in. Founded in 2021 by CEO Sarim Khan and CTO Hrituraj Singh, the company is chasing a very real bottleneck: cancer patients are living longer, which is great news, but it also means staff are stuck digging through years of physician notes, pathology reports, imaging, and even scanned faxes before they can do basic operational work. Khan put it plainly in the source interview: “We have seen medical records [with] thousands of pages of information.”

What does Triomics’ oncology AI platform actually do?

At the center of the product is OncoLLM, Triomics’ oncology-focused AI framework. It isn’t a single model. It’s a system of 8 models, ranging from 3B to 72B parameters, designed to reason at the patient level rather than just summarize one document at a time. That matters in oncology, where the signal is spread across a long timeline and buried in different record types.

The clearest example is PRISM, Triomics’ trial-enrollment software. In practice, PRISM pulls from both structured and unstructured EHR data. It checks a patient’s chart against active trial criteria and generates match summaries that coordinators and physicians can review before the visit. In one deployment at the Medical College of Wisconsin Cancer Center, the system screened 100% of upcoming visits across 5 disease teams against more than 100 recruiting trials after just a 2-hour onboarding workflow for coordinators.

That’s only one layer of the product now. Triomics started with clinical trial matching, but as large language models got better, it expanded into verifiable patient summaries for appointment prep. It also added data-curation tools that support quality reporting, cohort analysis, precision oncology, and cancer registry workflows. The company’s 2024 materials also described Harmony, a product for curation and reporting, alongside software embedded into health-system EHRs for task-specific work rather than generic chatbot-style assistance.

The before-and-after is pretty simple. Before Triomics, staff manually read charts for hours. They extract evidence by hand and repeat the same review process across every trial, visit, or reporting obligation. After Triomics, the software does the first pass in minutes and surfaces evidence-backed summaries inside the tools clinicians already use. In published results highlighted by the company, PRISM achieved more than 95% accuracy in placing the correct trial within its top 3 recommendations.

Who founded Triomics, and why does this oncology AI startup have investor backing?

The founding story

Triomics was founded in 2021 by Sarim Khan and Hrituraj Singh. The pairing makes sense on paper and, honestly, that’s rare. Khan came from chemical engineering and research experience in tissue engineering and neuroscience, while Singh had worked at Adobe Research on language models and reinforcement learning. They were also college friends, which usually helps when you’re trying to build a company in a category where the sales cycles are long and the consequences of errors are brutal.

Their original wedge was clinical trial matching. And that wasn’t random. They saw that a lot of hospital software could already work with the tidy 20% of health data stored in structured fields, but the harder 80% sat in free text and document chaos. Oncology was an extreme version of that problem. So Triomics went after the specialty first and then widened the product as LLMs became capable enough to handle more than trial screening.

Why the founders fit this category

Khan brings the biomedical lens. Singh brings the model-building depth. That’s a useful mix when your customer doesn’t want a flashy copilot — they want software that can survive review by oncologists, trial coordinators, and compliance teams.

Triomics also didn’t build in isolation. The company worked with Medical College of Wisconsin researchers on OncoLLM. It has also leaned hard into consortium-style validation around safety and benchmarking. Its leadership has pointed to COLT, a collaboration involving more than 20 NCI-designated cancer centers and Ci4CC, as part of that effort. In a field like oncology, that kind of institutional co-development matters a lot more than a polished demo.

Traction and the funding

Triomics’ enterprise customer base expanded 4x over the past year, helping push annualized recurring revenue up 10x. The customer list is getting serious. Memorial Sloan Kettering and Yale Cancer Center already use Triomics, while Y Combinator says the company is trusted by 4 of the top 10 Best Hospitals for Cancer ranked by U.S. News. Mount Sinai also rolled out PRISM systemwide in early 2026, becoming the first NCI-designated Comprehensive Cancer Center in New York City to deploy the tool for enterprise clinical trial matching.

The new money follows Triomics’ $15 million Series A in May 2024. That earlier round included Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator. Now Battery Ventures is stepping in to lead the Series B. Investors see something bigger here than a single workflow feature.

How does Triomics compare with Abridge, Nuance, and legacy workflows?

Triomics’ closest overlap with Abridge and Microsoft’s Nuance products is chart summarization, but the products aren’t really the same thing. Abridge turns clinical conversations into documentation and billable outputs. Microsoft Dragon Copilot combines dictation, ambient listening, and workflow support across general clinical documentation. Triomics is aiming at a narrower but thornier problem: making sense of longitudinal oncology records for tasks like trial eligibility, pre-charting, quality programs, and tumor registry submission.

The real incumbent still isn’t software. It’s manual labor. Nurses, coordinators, and admin staff are still reviewing huge charts by hand because generic AI tools don’t reliably understand oncology nuance. That’s the company’s core pitch, and it’s why Khan argues cancer centers such as MSK and Yale have chosen Triomics over broader-purpose assistants. The bet is that domain specificity beats generality when the workflow is specialized, highly regulated, and expensive to get wrong.

Why this oncology AI startup’s $22M round matters

The obvious read is that Triomics now has the capital to keep broadening from trial matching into a fuller oncology operations stack. That’s where the company has been heading for a while — first matching, then patient summaries, then registry and quality workflows. If that works, Triomics stops being a point tool and starts becoming infrastructure for cancer centers.

That matters for customers because oncology admin work doesn’t sit neatly in one place. A patient’s case can stretch over years, bounce across sites of care, and generate a chart that’s too dense for generic summarizers to handle well. A tool that can shrink appointment prep time and automate mandatory reporting buys back something rare in cancer care: staff attention. That’s valuable even before you get to trial enrollment.

There’s also a harsher reason this round matters. Healthcare AI is crowded now. Ambient scribes are everywhere. EHR vendors are shipping their own copilots. So for a startup to raise a Series B here, it usually needs more than a cool model — it needs evidence, workflow fit, and customers that will stick. Triomics understands that. Its emphasis on oncology-specific training, published validation work, and deployment inside real cancer centers suggests a company trying to build defensibility the boring way.

How big is the market for oncology AI software?

The most relevant adjacent market here is oncology information systems. That market was worth about $2.94 billion in 2024 and is projected to reach roughly $4.69 billion by 2030, with an 8.1% CAGR from 2025 through 2030. North America accounted for 39.7% of the market in 2024, which helps explain why startups like Triomics are targeting U.S. cancer centers first.

The timing also makes sense at the workflow level. Fewer than 10% of adult oncology patients enroll in clinical trials, and one reason is painfully simple: matching is still labor-intensive, fragmented, and easy to miss in day-to-day care. When records include free-text notes, pathology, imaging, genomic reports, and faxed documents, software that can actually reason across all of it has a much bigger opening than another generic AI note tool.

The broader healthcare AI market is sending a mixed signal. On one hand, ambient scribes became a $600 million category in 2025 after 2.4x year-over-year growth. On the other, Menlo Ventures says switching costs are low, pricing pressure is rising, and customers increasingly expect scribes to expand beyond documentation into more durable workflows. That’s relevant for Triomics because it suggests vertical, workflow-deep products may have a better shot at lasting value than standalone summarization tools.

Conclusion

Triomics looks like the kind of oncology AI startup investors want right now: focused, evidence-heavy, and pointed at work that hospitals already pay people to do manually.

But the next phase is harder than the last one. It’s one thing to prove an oncology model can read a chart. It’s another to become the default workflow layer across trial matching, pre-charting, and registry operations at major cancer centers. The company just raised $22 million to make that case.

Read how Tiea Connectors raised ₹77 Cr in Series A funding to build high-performance electrical connectors and interconnect systems for EV, aerospace, defence, and avionics manufacturers in India.

FAQ

– What funding did Triomics raise in 2026? 

 Triomics raised a $22 million Series B round announced on May 27, 2026. Battery Ventures led the financing, and returning investors included Nexus Venture Partners, Lightspeed, and Y Combinator.

– How does Triomics work for cancer centers? 

 Triomics uses an oncology-specific AI framework called OncoLLM to process both structured and unstructured patient records. It then powers workflow tools such as PRISM for clinical trial matching. Instead of only summarizing a note, it evaluates longitudinal charts, checks eligibility against trial criteria, and produces evidence-backed summaries for coordinators and physicians inside existing clinical workflows.

– Who founded Triomics? 

 Triomics was founded in 2021 by Sarim Khan and Hrituraj Singh. Khan’s background spans chemical engineering plus tissue engineering and neuroscience research, while Singh previously worked at Adobe Research on language models and reinforcement learning before becoming Triomics’ CTO.

– Is Triomics an ambient scribe company or an oncology software company? 

 It’s closer to an oncology software company than a pure ambient scribe vendor. Abridge and Microsoft Dragon Copilot mainly focus on turning clinician-patient conversations into documentation, while Triomics is built around oncology-specific chart review, trial enrollment, pre-charting, quality workflows, and registry reporting inside a market adjacent to oncology information systems.

Tiea Connectors makes high-performance electrical connectors and contact systems for sectors where failure isn’t an option. The Bengaluru-linked hardware startup has raised ₹77 crore in Series A funding led by IvyCap Ventures, with Jamwant Ventures, 8X Ventures, and a set of HNI angel investors also joining the round. That matters because India still imports a lot of precision interconnect hardware for EVs, aerospace, defence, and avionics. Local manufacturers that can design, tool, test, and scale these parts are still rare. Founded in 2020 by Ajith Sasidharan and Punit Shridhar Joshi, Tiea is trying to build that missing layer.

What does Tiea Connectors make and how does it work?

Tiea Connectors designs and manufactures electrical connectors, precision contacts, connector housings, stamped terminals, and cable-and-harness assemblies for OEMs and product teams. In plain English, it builds the small but mission-critical parts that let power and data move reliably inside vehicles, charging systems, drones, industrial electronics, defence equipment, and avionics hardware.

Its workflow is more vertically integrated than what a lot of small hardware suppliers can manage. An OEM can come in with an application requirement. Tiea then handles connector architecture and material selection. It also takes on rapid prototyping, tooling, validation, and scaled manufacturing. That matters. It cuts out the usual mess of splitting work between a design consultant, a toolroom, and a contract manufacturer.

The product mix is unusually broad for a young interconnect company. Tiea lists standard and custom connectors, presstac contacts for EV charging and battery management systems, high-precision machined and stamped parts, gold-plated terminals for harsh environments, in-house injection-moulded connector housings, and custom cable assemblies. Some of its EV-focused contacts are built for high current loads and up to 100,000 mating cycles. That gives you a sense of the reliability bar it’s chasing.

The before-and-after story for customers is obvious. Before, an Indian OEM in a niche category often had to import connector systems, wait on long qualification cycles, and accept whatever catalog part a global supplier was willing to ship. After, the same buyer gets a local engineering partner that can customize around space limits, vibration, heat, compliance needs, and cost targets without sending the whole program overseas.

Who founded Tiea Connectors and what has it built so far?

Founded by two engineers who knew the supply gap

Tiea was founded in 2020 by Ajith Sasidharan and Punit Shridhar Joshi. The two had worked together earlier at HPCL, then left to start the company after seeing how dependent Indian manufacturers still were on imported connector and contact solutions. That origin story fits the product. This isn’t a team that stumbled into hardware because it looked trendy.

The company started by focusing on miniature and customized electronic connectors. It has since widened into high-performance interconnect systems for electric mobility, aerospace, defence, avionics, and other emerging applications. Tiea also works as an original design manufacturer for tech-focused OEMs that want a partner to own connector design and manufacturing, not just assemble to print.

Tiea was incubated at IISc Bengaluru’s Foundation for Science and Innovation Development. It has also been linked with defence-focused development through the iDEX Challenge. That’s a decent signal that its ambitions aren’t limited to commodity parts.

Why the founders had a real shot at this

Ajith Sasidharan is a College of Engineering Trivandrum alumnus and has built his career around operations, business development, and interconnect products. Punit Shridhar Joshi, who is identified publicly as Tiea’s CTO, studied at NITK and brings the technical depth the category demands. That split works well for a manufacturing startup. One founder stays close to execution and growth. The other stays close to engineering and product.

That matters more in connectors than most people think. This category punishes weak process control. You don’t win because your pitch deck sounds smart. You win because tolerances stay tight, materials behave the way they should, tooling doesn’t drift, and a part still works after vibration, thermal cycling, and repeated mating. Tiea’s pitch is basically that it can do the hard bit in-house.

Its internal strengths line up with that claim: product architecture, rapid prototyping, tooling development, material engineering, miniaturisation, precision manufacturing, and application-specific customization. That’s a lot of capability for a startup that’s only been around since 2020.

Early traction, prior rounds, and the Series A

Tiea isn’t operating like a lab project. It is delivering 5 million parts a month, has 70+ active projects, and serves 50+ customers. A prior update around its earlier fundraise said the business had grown 4x in FY25 and was already running at 90% of manufacturing capacity. For a hardware company, that’s the kind of signal investors care about.

It also has a manufacturing facility in Dharwad, Karnataka, with in-house tooling, stamping, moulding, assembly, and testing. That setup is central to the thesis. If you’re selling into defence electronics, EV systems, or aerospace programs, you can’t fake process ownership for long.

This Series A comes after smaller earlier rounds, including a ₹3 crore angel raise in 2022 and a ₹22 crore round announced later as the business scaled. IvyCap Ventures led the new ₹77 crore round. Jamwant Ventures and 8X Ventures also came in, along with select high-net-worth angel investors. Tiea says the money will go into manufacturing expansion and stronger R&D and product engineering. It also plans more automation and technology integration, along with broader scaling in India and overseas.

How Tiea competes in a connector market ruled by imports

Tiea is entering a category long dominated by global connector majors and imported parts catalogs. In practice, Indian OEMs often buy from large multinational suppliers or rely on fragmented local vendors that can machine or mould a part but can’t own the full engineering cycle. That gap is where Tiea is trying to sit.

Its edge isn’t that it’s inventing connectors from scratch. It offers local design ownership and faster tooling iteration. It also handles customization, validation, and scaled manufacturing under one roof. For customers in EVs, aerospace, and defence, that can mean shorter lead times, less import dependence, easier localization, and products built around Indian operating conditions instead of generic global specs.

That’s also why IvyCap’s bet makes sense. Vikram Gupta, the firm’s founder and managing partner, pointed to Tiea’s strength in innovation, precision engineering, product customization, and scalable manufacturing. The investors aren’t just backing a component seller. They’re backing a domestic supplier that could become hard to replace once it’s qualified into critical programs.

Why does Tiea Connectors funding matter now?

Because this round changes the kind of company Tiea can become.

A small connector maker can survive on engineering skill and founder hustle for only so long. Once orders scale, the real pressure moves to automation, repeatability, quality systems, and production throughput. That’s exactly where Tiea says the fresh capital is going. Not into vague brand building. Into machines, process depth, product engineering, and more factory muscle.

There’s a timing angle here too. Ajith Sasidharan has framed the demand pull around “electrification, intelligent systems, and high-reliability applications.” He’s right. Those categories don’t just need more components. They need better interconnects. A drone, an EV platform, or an avionics unit is only as dependable as the weakest connector buried inside it.

The strategic value is bigger than the part itself. If Tiea can move from a promising domestic supplier to a deeply embedded one, it could become part of the supply chain logic for Indian OEMs that want less exposure to imported precision hardware.

How big is the market for high-performance connectors in India?

It’s not a tiny niche anymore. India’s automotive connectors market was valued at $746 million in 2024 and is projected to reach about $1.2 billion by 2033. That’s just one slice of the opportunity, and Tiea isn’t limited to automotive. It also sells into electric mobility, defence, aerospace, drones, consumer electronics, and industrial systems.

The structural trend is simple. Every time a machine gets more electrified, more software-heavy, or more safety-critical, connector content goes up. EVs need high-voltage power connectors and battery-management interconnects. Aerospace and defence systems need ruggedized, high-reliability parts that survive heat, shock, and vibration. Avionics and drones need lightweight connectors that still hold signal integrity. None of that is easy manufacturing.

India’s policy push toward domestic electronics production helps too, but policy alone doesn’t build a supplier base. You still need companies that can do toolmaking and moulding. You also need stamping, validation, and quality control at production scale. That’s why this category is getting more interesting now than it was 5 years ago.

What should you watch after Tiea Connectors funding?

The next test for Tiea won’t be fundraising. It’ll be execution.

Can it turn more factory capacity and automation into consistent quality across EV, aerospace, and defence-grade programs? Can it win deeper design-in positions with OEMs instead of staying a useful but replaceable vendor?

Read how SOND raised $7M to launch Dreambuds, AI sleep earbuds that monitor biometric signals and adjust audio in real time to help users fall asleep and stay asleep.

FAQ

– What is the Tiea Connectors funding round about? 

 Tiea Connectors has raised ₹77 crore in a Series A round led by IvyCap Ventures. Jamwant Ventures, 8X Ventures, and a group of HNI angel investors also participated, and the money is meant to expand manufacturing, strengthen R&D, and add more automation.

– How does Tiea Connectors actually make money? 

 Tiea sells connectors, contacts, precision components, and integrated interconnect solutions to OEMs and manufacturers. It also works as an ODM partner, which means it can take responsibility for product definition and design. It also handles validation, tooling, and scaled production instead of just supplying a standard part.

– Who founded Tiea Connectors? 

 Tiea was founded in 2020 by Ajith Sasidharan and Punit Shridhar Joshi. The founders were former colleagues at HPCL, and the company later grew through IISc incubation and deeper work in EV, defence, and aerospace-grade interconnect products.

– Is Tiea Connectors an EV startup or a defence startup? 

 It’s really an interconnect manufacturing startup that sells into both. EV charging, battery management systems, aerospace, defence, avionics, drones, and industrial electronics all need reliable connector systems, and Tiea is building for that broader category rather than one single end market.

SOND makes AI sleep earbuds that monitor your body overnight and change what you hear in real time. On Wednesday, May 27, 2026, the Boston startup came out of stealth with $7 million in funding and a new product called Dreambuds. The pitch is simple: most sleep gadgets tell you what went wrong after the fact, while SOND wants to intervene while you’re still trying to fall asleep or get back to sleep. The company was founded in February 2022 by CEO Yadid Ayzenberg and CTO Amir Lazarovich, two MIT-connected founders who think sleep audio should act more like a live system than a passive player.

What are SOND’s AI sleep earbuds and how do they work?

Dreambuds are a closed-loop, in-ear sleep system. In practice, that means the earbuds collect 12 physiological signals — including respiration, heart-rate variability, cardiorespiratory coupling, sleep stage, body position, snoring, and seismocardiography — then send that data to a cloud-based AI sleep coach that picks or generates audio in response. It’s not just playing white noise all night. It’s meant to notice what’s happening in your body and adjust the intervention while you sleep.

The user flow is more ambitious than standard sleep earbuds. You take the buds out, they resume your sleep plan. The system can switch programs depending on whether you’re winding down, waking up, or stuck in the middle-of-the-night half-awake zone. SOND says users can talk to the coach with a double tap, ask for sleep insights, or request a specific sleep story. They can also choose a soundscape, breathing exercise, binaural beat session, or another program from its library of 500-plus audio tracks. Podcasts can stream through the case too, if that’s your thing.

There’s another important design choice here: Dreambuds don’t need a phone by the pillow. The charging case includes Wi-Fi and Bluetooth. It also has an OLED display, physical buttons, built-in storage, and a speaker that can still fire an alarm if you fall asleep before putting the earbuds in. That phone-free setup is one of the sharper parts of the pitch, and Ayzenberg’s line about it is memorable: giving an insomniac a phone is “like running an AA meeting in a liquor store.”

SOND has also packed in a few details the launch article only hinted at. The free Core plan includes masking sounds and biometric tracking. It also includes nightly reports. A higher-tier Concierge plan adds personalized coaching, the 500-plus track library, and dream journaling. The buds can work offline with downloaded tracks stored in the case, the app includes a Bluetooth-based Find My Dreambuds tool, and battery life is targeted at up to 9 hours of overnight use. It’s a lot.

Who founded SOND and why now?

The founding story

SOND started in Boston in February 2022, but the founders’ connection goes back much further. Ayzenberg and Lazarovich met at MIT about 14 years earlier in a way that sounds almost too on-brand: Lazarovich had just moved into a family dorm without a mattress, and Ayzenberg gave him one from his room. That random sleep-related favor turned into a long friendship, then a company built around sleep.

Ayzenberg’s case for starting SOND came out of his time at Bose. He had led Bose’s sleep products business, launched Sleepbuds II, and spent years hearing a similar request from customers: they didn’t just want masking audio, they wanted sensing, coaching, and actual help improving sleep. Back then, he says, the hardware wasn’t ready to squeeze that many sensors into a tiny earbud without wrecking battery life. By the time Bose stepped away from the category, the technical constraints had shifted enough to make a new attempt possible.

Why these founders fit this category

Ayzenberg looks like a category-native founder because, frankly, he is one. Before Bose, he founded The Sync Project, a Boston startup that mapped music to physiological signals such as heart rate and heart-rate variability. Bose acquired that company in February 2018, which pulled him deeper into the overlap between audio, biosignals, and sleep. He also spent time at the MIT Media Lab, where his work sat close to affective computing and physiological sensing.

Lazarovich brings the systems side. The source article identifies him as a former senior software engineering manager at Google, and SOND frames the company as built by engineers from Bose, Google, and MIT. That matters because Dreambuds isn’t just an audio gadget. It’s earbuds and sensors. It’s embedded hardware, a connected case, cloud processing, voice interaction, and software that has to work when the user is half asleep and annoyed. Brutal stack.

Funding, traction, and where SOND sits against rivals

E14 Fund, Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele backed the financing. SOND hasn’t disclosed much on commercial traction yet because Dreambuds are still prelaunch. It has said it has run comfort studies and betas, is taking reservations now, plans a crowdfunding campaign, and is aiming for mass production in Q2 2026, with customer availability pegged to mid-2026 on the company’s FAQ.

The obvious direct rival is Ozlo, another sleep-earbud company created by ex-Bose engineers. Ozlo’s current product leans hard into passive blocking and streaming. It also includes biometric sensing, a smart case, and phone-free playback modes. The company announced a $12 million round in October 2024 on top of roughly $8 million raised through crowdfunding. Then there’s Soundcore, whose Sleep A20 sells for $179.99 and emphasizes passive noise blocking, side-sleeper comfort, sleep analytics, app control, and up to 14 hours in sleep mode.

That’s where SOND’s positioning gets interesting. Ozlo and Soundcore mostly help you block noise and stream audio. They also let you review sleep data. SOND is trying to sell something more aggressive: not sleep earbuds as a comfort accessory, but AI sleep earbuds that sense, decide, and intervene. Ayzenberg’s own framing is that Dreambuds are not what a hypothetical Bose Sleepbuds III would have been.

Why does this AI sleep earbuds round matter for SOND?

Because hardware is expensive, and sleep hardware with custom sensing is even worse.

A lot of startup funding headlines blur together. This one doesn’t. Dreambuds combine miniaturized sensors and audio hardware. They also rely on voice interaction, a networked charging case, cloud AI, and a companion app. Getting that from prototype to reliable consumer hardware is a capital problem as much as a product problem. $7 million won’t buy infinite runway, but it does buy time to turn a clever demo into a manufacturable device.

It also gives SOND a shot at building a business that isn’t pure hardware margin. The Core and Concierge split suggests the company wants recurring software revenue layered on top of the earbuds themselves. Investors tend to like that structure for good reason. If the product works, SOND isn’t limited to selling a pair of buds once and hoping customers come back in 3 years.

There’s a subtler signal here too. Bose exited sleep wearables. Ayzenberg still came back to the category anyway. That suggests he thinks the earlier failure was about timing and product scope, not a dead market.

How big is the market for AI sleep earbuds?

The raw market numbers are big enough to attract a lot of builders. Grand View Research sizes the global sleep aids market at $49.1 billion in 2025 and projects it to reach $95.2 billion by 2033, with North America holding a 41.4% share in 2025. That doesn’t mean sleep earbuds alone are a $49 billion business. But it does show why investors keep circling anything that sits between consumer audio, wellness, and sleep improvement.

The demand problem is also very real in the U.S. A CDC data brief published in April 2026 found that 30.5% of American adults got less than 7 hours of sleep in 2024. The same report said 15.4% had trouble falling asleep most days or every day, while 18.1% had trouble staying asleep. That’s a huge addressable group.

Timing matters too. Consumers are already used to wearables that score their readiness, chart their sleep stages, or tell them they had a rough night. What’s changing is the hardware and software stack: sensors are smaller, earbud form factors are more accepted, and cloud-connected systems can react in the moment instead of waiting until morning. SOND didn’t invent that shift, but it’s trying to push it one step further — from sleep tracking to sleep intervention.

Will AI sleep earbuds become more than a niche?

SOND has a credible founder story, a product idea that’s actually distinct, and enough capital to prove whether Dreambuds are more than a smart pitch deck.

But this category is unforgiving. People will tolerate buggy social apps. They won’t tolerate earbuds that die at 4 a.m., fall out, or overcomplicate bedtime. If SOND can ship reliable AI sleep earbuds on the timeline it’s promised, it could help redefine what sleep wearables are supposed to do.

Read how WeRoad raised a $58M Series C led by Airbnb to turn group travel and local meetups into a social platform for young travelers looking to connect beyond traditional booking sites.

FAQ

– What funding did SOND raise for Dreambuds? 

 SOND raised $7 million when it emerged from stealth on May 27, 2026. The investors included E14 Fund, Crosslink Capital, Ubiquity Ventures, Alumni Ventures, Meach Cove Capital, and Boston Scientific co-founder John Abele, which gives the round a mix of MIT ties, consumer-tech backing, and medtech credibility.

– How do SOND Dreambuds work? 

 Dreambuds are AI sleep earbuds that collect 12 physiological signals while you sleep and feed them into a cloud-based coach that changes the audio program in real time. The system can deliver masking sounds and guided exercises. It can also serve sleep stories and other audio responses, and it’s built to run from a connected charging case so users don’t need to keep grabbing their phone at night.

– Who founded SOND? 

 SOND was founded in February 2022 by Yadid Ayzenberg and Amir Lazarovich. Ayzenberg previously founded The Sync Project, which Bose acquired in 2018, and later led Bose’s sleep products work; Lazarovich came from Google and brings the software and systems background this product stack needs.

– Is SOND a sleep tech company or an audio hardware startup? 

 It’s really both, but sleep tech is the better label. Dreambuds sit inside the broader sleep aids market, which Grand View Research values at $49.1 billion in 2025, yet the company’s claim is that it’s building intervention-focused sleep wearables rather than just another pair of audio accessories.